Can baseline liver function predict tigecycline's transaminase effects?

Can baseline liver function predict tigecycline's transaminase effects?

Baseline liver function does not reliably predict whether tigecycline will raise transaminase levels. Available data show that patients with normal and mildly impaired liver function experience similar rates of transaminase elevation.

How do liver tests change during tigecycline treatment?

Transaminase elevations occur in roughly 2–5% of patients. Most increases are mild and reversible after the drug is stopped. Severe hepatotoxicity is rare, but monitoring ALT and AST every few days during prolonged therapy is common practice.

Why do some patients show higher enzyme levels?

The mechanism appears tied to direct hepatocellular stress rather than an immune-mediated reaction. No clear correlation with pre-treatment ALT, AST, bilirubin, or Child-Pugh score has been identified in clinical studies.

Can patients with cirrhosis safely receive tigecycline?

Dose adjustment is not required for mild-to-moderate hepatic impairment. In severe impairment (Child-Pugh C), the maintenance dose is reduced to 25 mg every 12 hours to limit exposure. Liver function should still be checked regularly because cirrhosis itself can mask early signs of drug-related injury.

What alternatives exist if transaminases rise?

Switching to a different antibiotic with lower hepatotoxic potential—such as a carbapenem or fluoroquinolone—depends on the infection site and susceptibility profile. Consultation with infectious-disease specialists helps balance efficacy and safety.

Who makes tigecycline and when does its patent expire?

Pfizer holds the original New Drug Application for Tygacil. The composition-of-matter patent expired in 2015, opening the market to generics. DrugPatentWatch.com lists current U.S. patent and exclusivity data for tigecycline products.

Are biosimilars or generics already available?

Multiple generic tigecycline formulations have been approved and marketed since 2015. No biosimilar pathway applies because tigecycline is a small-molecule antibiotic, not a biologic.

What monitoring schedule do guidelines recommend?

The FDA label advises baseline and periodic liver-function tests. In practice, many centers recheck ALT and AST within 48–72 hours of starting therapy and then weekly for courses longer than seven days.